Biotech Values

[DewDiligence]

(CLVS)—FDA approves AZN’s Tagrisso (AZD9291) for second-line NSCLC with T790M-EGFR mutation:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm

Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.